Using cost-effectiveness analysis to support policy change: varenicline and nicotine replacement therapy for smoking cessation in Jordan

References

• WHO. World Health Organization. Prevalence of tobacco smoking. Age-standardized prevalence of current tobacco smoking among persons aged 15 years and older (%), 2015: Male. Retreived from http://gamapserver.who.int/gho/interactive_charts/tobacco/use/atlas.html. 2015.
   Google Scholar
• Jaghbir M, Shreif S, Ahram M. Pattern of cigarette and waterpipe smoking in the adult population of Jordan. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2014;20(9):529-37.
   Google Scholar
• National Center for Chronic Disease P, Health Promotion Office on S, Health. Reports of the surgeon general. The health consequences of smoking-50 years of progress: a report of the surgeon general. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014.
   Google Scholar
• Ekpu VU, Brown AK. The economic impact of smoking and of reducing smoking prevalence: review of evidence. Tobacco Use Insights. 2015;8:1–35.
   PubMed Web of Science ®Google Scholar
• Goodchild M, Nargis N, Tursan d’Espaignet E. Global economic cost of smoking-attributable diseases. Tob Control. 2018;27(1):58–64.
   PubMed Web of Science ®Google Scholar
• Jaghbir M, Shareif S, Ahram M. Quitting smoking and utilization of smoking cessation services in Jordan: a population-based survey. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2014;20(9):538-46.
   Google Scholar
• Ayub H, Obeidat N, Leischow S, Glynn T, Hawari F. Jordan tobacco dependence treatment guidelines: rationale and development. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2016;21(11):844-50.
   Google Scholar
• U.S. Department of Health and Human Services. Smoking cessation. A report of the surgeon general, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, office on smoking and health, 2020. Atlanta, GA; 2020.
   Google Scholar
• Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet (London, England). 2016;387(10037):2507–2520.
   PubMed Web of Science ®Google Scholar
• Barua RS, Rigotti NA, Benowitz NL, Cummings KM, Jazayeri MA, Morris PB, et al. 2018 ACC expert consensus decision pathway on tobacco cessation treatment: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2018;72(25):3332–3365.
   PubMed Web of Science ®Google Scholar
• Berg ML, Cheung KL, Hiligsmann M, Evers S, de Kinderen RJA, Kulchaitanaroaj P, et al. Model-based economic evaluations in smoking cessation and their transferability to new contexts: a systematic review. Addiction. 2017;112(6):946–967.
   PubMed Web of Science ®Google Scholar
• DOS. Department of Statistics. Jordan In figures 2018. http://dosweb.dos.gov.jo/products/jordan-in-figure2018/. 2018.
   Google Scholar
• DOS. Department of Statistics. Jordan statistical yearbook. http://dosweb.dos.gov.jo/DataBank/yearbook/YearBook2016_eng.pdf. 2016.
   Google Scholar
• Hagen G, Wisloff T, Klemp M. NIPH systematic reviews. Cost-effectiveness of varenicline, bupropion and nicotine replacement therapy for smoking cessation. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH) Copyright (c)2010 by The Norwegian Institute of Public Health (NIPH); 2010.
   Google Scholar
• Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers. PharmacoEconomics. 2008;26(6):497–511.
   PubMed Web of Science ®Google Scholar
• Abughosh S, Wu IH, Hawari F, Peters RJ, Yang M. Predictors of intention to quit cigarette smoking among Jordanian adults. Epidemiol. 2011;1:103.
   Google Scholar
• Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. The Cochrane database of systematic reviews. 2016 (5):Cd006103.
   Google Scholar
• Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;5:Cd000146.
   PubMedGoogle Scholar
• Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. PharmacoEconomics. 2018;36(7):745–758.
   PubMed Web of Science ®Google Scholar
• Baker CL, Pietri G. A cost-effectiveness analysis of varenicline for smoking cessation using data from the EAGLES trial. Clinicoecon Outcomes Res. 2018;10:67–74.
   PubMed Web of Science ®Google Scholar
• Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008.
   Google Scholar
• Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation. The Cochrane database of systematic reviews. 2013(5):Cd000165.
   Google Scholar
• Taylor D, Henley V, Thun M, Sloan F. Benefits of smoking cessation for longevity. Am J Public Health. 2002;92(6):990–996.
   PubMed Web of Science ®Google Scholar
• WHO. World Health Organization Commission on Macroeconomics and Health: macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva, World Health Organization 2001. Retrieved from http://www1.worldbank.org/publicsector/pe/PEAMMarch2005/CMHReport.pdf. 2001.
   Google Scholar
• Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929–935.
   PubMed Web of Science ®Google Scholar
• Robinson LA, Hammitt JK, Chang AY, Resch S. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017;32(1):141–145.
   PubMed Web of Science ®Google Scholar
• IMF. International Monetary Fund. World Economic and Financial Surveys, World Economic Outlook database: Jordan. Retrieved from https://www.imf.org/external/pubs/ft/weo/2019/01/weodata/index.aspx. 2019.
   Google Scholar
• Hughes JR, Peters EN, Naud S. Relapse to smoking after 1 year of abstinence: a meta-analysis. Addict Behav. 2008;33(12):1516-20.
   Google Scholar
• JFDA. Jordanian Food & Drug Administration. Drug pricing. Retrieved from http://www.jfda.jo/Pages/viewpage.aspx?pageID=184. 2019.
   Google Scholar
• TreeAge. TreeAge Pro 2018, R??? TreeAge Software, Williamstown, MA; software available at http://www.treeage.com. 2018.
   Google Scholar
• Keating GM, Lyseng-Williamson KA. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation. PharmacoEconomics. 2010;28(3):231–254.
   PubMed Web of Science ®Google Scholar
• JPD. Joint Procurement Department, Jordan. Annual Report, 2017. Retrieved from http://jpd.gov.jo/echobusv3.0/SystemAssets/7fc4af63-d6ee-469c-a460-155962e84286.pdf. 2016.
   Google Scholar
• Hendrick RE, Helvie MA. Mammography screening: a new estimate of number needed to screen to prevent one breast cancer death. AJR Am J Roentgenol. 2012;198(3):723–728.
   PubMed Web of Science ®Google Scholar
• OCP VS, Williams S, Barchilon V, Baxter N, Jawad M, Katsaounou PA, et al. Treating tobacco dependence: guidance for primary care on life-saving interventions. Position statement of the IPCRG. NPJ Prim Care Respir Med. 2017;27(1):38
   PubMedGoogle Scholar